|
Health care cost impact associated with adverse events (AEs) among treatments in third-line+ (3L+) relapsed/refractory follicular lymphoma (R/R FL). |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; BeiGene; Bristol-Myers Squibb; Epizyme; GlaxoSmithKline; Janssen; Jazz Pharmaceuticals; Karyopharm Therapeutics; MorphoSys; Seagen; Takeda |
Speakers' Bureau - Abbvie; Amgen; AstraZeneca; BeiGene; Bristol-Myers Squibb; Epizyme; GlaxoSmithKline; Janssen; Jazz Pharmaceuticals; Karyopharm Therapeutics; MorphoSys; Seagen; Takeda |
|
|
|
Stock and Other Ownership Interests - Epizyme; Sage Therapeutics |
|
|
Employment - Abbvie (I); Analysis Group |
Stock and Other Ownership Interests - Abbvie (I) |
|
|
Employment - Analysis Group |
|
|
Employment - Analysis Group |
|
|
|
Stock and Other Ownership Interests - Epizyme |